No Patient or Illness to be Treated? The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)Vedder, H., 2015, In : Journal of European Competition Law & Practice. 6, 9, p. 664-668 5 p.
Research output: Contribution to journal › Article › Academic › peer-review
This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.
|Number of pages||5|
|Journal||Journal of European Competition Law & Practice|
|Early online date||25-Aug-2015|
|Publication status||Published - 2015|
- Pharmaceutical markets, competition law